Angiotensin Converting Enzyme Inhibitors Are Associated with the Need for Increased Recombinant Human Erythropoietin Maintenance Doses in Hemodialysis Patients (original) (raw)
Article navigation
Research Articles| December 23 2008
2nd Department of Internal Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan
Search for other works by this author on:
2nd Department of Internal Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan
Search for other works by this author on:
2nd Department of Internal Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan
Search for other works by this author on:
2nd Department of Internal Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan
Search for other works by this author on:
Nephron (1997) 77 (2): 164–168.
Abstract
The influence of angiotensin-converting enzyme inhibitors (ACEIs) on recombinant human erythropoietin (rhEPO) maintenance doses in hemodialysis patients was studied. One hundred and eight chronic hemodialysis patients (55 males and 53 females, mean age 61.2 ± 12.6 years) were investigated. The rhEPO maintenance doses in the ACEI-treated group (n = 49) were 101.7 ± 51.7 U/kg/week and in the nontreated group (n = 59) 79.2 ± 37.8 U/kg/week (p < 0.05). No difference was observed in hematocrit between the ACEI-treated and nontreated groups. In stepwise regression analysis, the parameters associated with increased rhEPO maintenance doses were female gender, ACEI administration, low total iron binding capacity, and low serum free carnitine levels. In conclusion, ACEI administration might reduce the response to rhEPO. In hemodialysis patients who need high-dose rhEPO to maintain the target hematocrit in the absence of iron deficiency, hyperparathyroidism, infection, malignancy, malnutrition, and aluminum toxicity, ACEI administration should be considered.
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 